| Protein Name: | 5-hydroxytryptamine 3 receptor (P46098) |
|---|---|
| Gene Name: | Not Available |
| Description: | Phospholipase A2, spermatozoa (EC 3 1 1 4) (Phosphatidylcholine 2- acylhydrolase) (Fragment) |
| PDB ID: | |
| Protein Family: | |
| Protein Category: | Ion Channels |
This panel provides drug-protein interaction and their ADRs along with references
| Interacting Drugs | Toxicity | Mechanism | Reference |
|---|---|---|---|
| Cisplatin | Nausea | Nausea and vomiting associated with the use of 5 HT uptake inhibitors are due to stimulation of 5HT3 receptors. [ ADR Type 1 ] | Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties |
| Cisplatin | Vomiting | Nausea and vomiting associated with the use of 5 HT uptake inhibitors are due to stimulation of 5HT3 receptors. [ ADR Type 1 ] | Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties |
| Gabapentin | Anxiety | Adverse effects may@ however@ occur through the stimulation of different serotonin receptor subtypes (5-HT2A@ 5-HT2B@ and 5-HT3)@ leading to anxiety [ ADR Type 2 ] | Cell-mediated side effects of psychopharmacological treatment |
| Gabapentin | Nausea | Adverse effects may@ however@ occur through the stimulation of different serotonin receptor subtypes (5-HT2A@ 5-HT2B@ and 5-HT3)@ leading to nausea [ ADR Type 2 ] | Cell-mediated side effects of psychopharmacological treatment |
| Gabapentin | Sleep Disturbances | Adverse effects may@ however@ occur through the stimulation of different serotonin receptor subtypes (5-HT2A@ 5-HT2B@ and 5-HT3)@ leading to sleep disturbances [ ADR Type 2 ] | Cell-mediated side effects of psychopharmacological treatment |
This panel provides information on drug category
| Toxicity | Source |
|---|